Orbimed Advisors LLC Sells 41,100 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Orbimed Advisors LLC lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 963,400 shares of the biotechnology company's stock after selling 41,100 shares during the quarter. Sarepta Therapeutics accounts for 2.6% of Orbimed Advisors LLC's investment portfolio, making the stock its 8th largest position. Orbimed Advisors LLC owned approximately 1.01% of Sarepta Therapeutics worth $117,140,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the company. Manchester Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $36,000. Steward Partners Investment Advisory LLC lifted its position in shares of Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after acquiring an additional 216 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 7.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SRPT. Needham & Company LLC reduced their price target on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group reduced their price objective on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Guggenheim reduced their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Morgan Stanley reduced their price objective on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $131.22.

Sarepta Therapeutics Stock Up 0.3%

Shares of SRPT opened at $36.37 on Tuesday. The business has a fifty day moving average of $65.42 and a 200 day moving average of $99.77. The company has a market cap of $3.57 billion, a PE ratio of 29.10 and a beta of 0.85. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 52-week low of $35.46 and a 52-week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter in the prior year, the business posted $0.73 EPS. The business's quarterly revenue was up 80.2% on a year-over-year basis. On average, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.